The global Mycoplasma Testing Market is expanding rapidly as pharmaceutical and biotechnology companies, research institutions, cell banks, and contract research organizations place greater emphasis on contamination control and product safety. Mycoplasma contamination can compromise cell cultures, research results, and biopharmaceutical production, making reliable testing an essential part of quality-control workflows. The increasing development of biologics, vaccines, cell therapies, regenerative medicine products, and other advanced biological therapies is further strengthening demand for accurate and rapid mycoplasma detection technologies. According to Grand View Research, the market was valued at USD 1.1 billion in 2025, is estimated to reach USD 1.3 billion in 2026, and is projected to reach USD 2.8 billion by 2033, expanding at a CAGR of 12.0% from 2026 to 2033. 

Download a free sample copy of the Mycoplasma Testing Market report to understand detailed coverage and inclusions in the final report

Market Segmentation 

The market is structured across product, test method, technology, application, and end use, with kits and reagents, PCR, cell line testing, and pharmaceutical and biotechnology companies representing important leading segments.

• By Product — Kits & Reagents Lead: The kits and reagents segment accounted for 56.0% of market revenue in 2025. These products are essential for routine testing and generate recurring demand across research laboratories and regulated quality-control environments. Ready-to-use testing solutions can simplify laboratory workflows while supporting consistent contamination detection. Services are expected to register the fastest growth during the forecast period as companies increasingly outsource specialized testing, method validation, auditing, and related quality-control activities. 

• By Test Method — Integrated/Automated Leads: The integrated/automated segment held a 41.5% revenue share in 2025, reflecting growing interest in automated workflows that can improve testing consistency and reduce manual intervention. 

• By Technology — PCR Dominates: PCR accounted for 47.5% of revenue in 2025, making it the leading technology segment. PCR-based testing is valued for its sensitivity and rapid detection capabilities. 

• By Application — Cell Line Testing Leads: The cell line testing segment represented 41.2% of revenue in 2025 and is also expected to register the fastest growth during the forecast period. The increasing use of cell cultures in pharmaceutical research, biologics development, and advanced therapies is creating greater demand for routine contamination screening. 

• By End Use — Pharmaceutical & Biotechnology Companies: Pharmaceutical and biotechnology companies accounted for 35.4% of revenue in 2025. These organizations require mycoplasma testing to support biological safety, raw-material quality, cell-culture integrity, and manufacturing quality control. Increasing investment in drug discovery and biopharmaceutical development is expected to sustain demand from this segment. 

Primary Growth Drivers

• Stringent Regulatory Requirements: Regulatory agencies require rigorous contamination testing to ensure the quality and safety of biological products. These requirements create consistent demand for mycoplasma detection throughout development and manufacturing workflows. 

• Expansion of Biologics and Cell Therapies: The growing development of biologics, vaccines, cell therapies, and regenerative medicine products is increasing the importance of reliable contamination monitoring. As cell-based manufacturing becomes more sophisticated, sensitive testing solutions are increasingly required to protect product quality. 

• Demand for Faster Testing: Conventional microbial culture techniques can require lengthy incubation periods. PCR and other rapid technologies provide faster detection, helping laboratories identify contamination earlier and supporting more efficient manufacturing and research workflows. 

• Growth of Outsourced Testing: Pharmaceutical and biotechnology companies are increasingly using contract research and testing organizations to access specialized laboratory capabilities without maintaining all testing infrastructure internally. This trend is supporting the services segment and expanding the role of specialized testing providers. 

• Rising Life Sciences R&D Investment: Increasing investments in biotechnology and biopharmaceutical research are creating additional demand for cell culture and contamination-monitoring technologies. The growing number of research programs and biological manufacturing facilities is strengthening the long-term opportunity for mycoplasma testing. 

Looking for more specific insights? Customize this report to suite your business needs

Regional Dynamics

• North America — Market Leader: North America dominated the global industry with a 40.5% revenue share in 2025. The region benefits from strong biotechnology and biopharmaceutical activity, advanced healthcare infrastructure, significant R&D investment, and stringent regulatory requirements. The U.S. represented the largest country-level market in 2025. 

• Asia Pacific — Fastest Growing: Asia Pacific is expected to register the fastest CAGR during the 2026–2033 forecast period. Expanding biotechnology manufacturing, increasing research activity, improvements in biosafety standards, and growing pharmaceutical production are creating significant opportunities throughout the region. 

Key Industry Players

The following key companies have been profiled for this study on the mycoplasma testing market

• Thermo Fisher Scientific, Inc.

• Merck & Co., Inc.

• Lonza Group AG

• Charles River Laboratories International, Inc.

• PromoCell GmbH

• Asahi Kasei Medical Co., Ltd.

• Sartorius AG

• InvivoGen

• Eurofins Scientific

• (ATCC) American Type Culture Collection

Companies are focusing on new product launches, technological advancements, strategic collaborations, acquisitions, and geographic expansion to strengthen their presence. The competitive landscape is increasingly centered on faster PCR-based solutions, automated workflows, testing services, and technologies designed to improve sensitivity and laboratory efficiency.

Primary Market Challenges

• Testing Complexity: Different biological products and cell systems can require carefully validated testing protocols, increasing the complexity of laboratory workflows. 

• High Technology Costs: Automated instruments and advanced molecular testing platforms can require significant investments, particularly for smaller laboratories. 

• Skilled Personnel: Accurate testing requires trained laboratory professionals who understand sample preparation, assay validation, quality control, and interpretation. 

• Contamination Risks: Mycoplasma contamination can occur at different stages of cell culture and manufacturing, requiring consistent monitoring rather than one-time testing. 

• Regulatory Compliance: Testing laboratories and manufacturers must maintain appropriate validation, documentation, and quality systems to satisfy regulatory expectations.

Related Reports: 

• Laboratory Proficiency Testing Market Size, Share & Trends Analysis Report By Industry (Clinical Diagnostics, Pharmaceuticals, Microbiology, Cannabis), By Technology (Cell Culture, PCR, Immunoassays), By End-use, By Region, And Segment Forecasts

• Legionella Testing Market Size, Share, & Trends Analysis Report By Type (Water Testing, IVD Testing), By End Use (Microbial Culture, Direct Fluorescent Antibody (DFA) Stain, PCR, Others), By Region, And Segment Forecasts

• Laboratory Developed Tests Market Size, Share & Trends Analysis Report By Technology (Immunoassay, Molecular Diagnostics, Microbiology, Clinical Chemistry), By Application (Oncology, Nutritional & Metabolic Disease), By Region, And Segment Forecasts